殷雷 (Yin, Lei)

wuhan university教授博导

H指数:0

被引数:0

个人简介

"殷雷，教授，博士生导师，重庆医科大学附属儿童医院国家临床医学研究中心，国家高层次青年人才，重庆高层次引进人才。主要从事抗原识别及基因编辑医药挖掘，发表学术论文近50篇。以第一作者/通讯作者在《Immunity》、《Nature communications》（2篇）、《Genome Biology》、《PNAS》（2篇）、《Science Advances》、《EClinicalMedicine》、《Molecular Therapy》、《Plos Biology》（2篇）等专业TOP期刊上发表研究成果30余篇，3篇配发特邀评论重点介绍，一篇入选杂志封面并入选ESI高被引。主持国家重点重大课题和国家自然科学基金多项，获省部级科技进步奖一等奖，担任中国生物物理学会人工智能生物学分会委员，武汉生物物理学会理事长，国家重点研发计划二审专家等。近5年来，围绕抗原和TCR/BCR的筛选鉴定、单细胞TCR/BCR和空间TCR/BCR大数据研究、分子互作和结构分析、低脱靶多基因编辑和相关医药挖掘等方面建立了新的技术平台体系，开发出多个自主产权的抗原识别增强新方法、低脱靶Cas12a基因编辑酶和小分子候选药物,授权专利5项，转化一项。组建抗原识别数字平台和基因编辑平台，每年招收硕博士2-4人和医院固定研究人员1-2人。\n教育背景及工作简历\n1998-2002武汉大学生命科学学院基地班专业学士\n2002-2007中国科学院生物物理研究所生物大分子国家重点实验室硕士/博士\n2008-2013美国霍华德休斯医学研究所（HHMI）研究助理\n导师：John Kappler院士Philippa Marrack院士（英国皇家学会会员）\n2014-2024武汉大学生命科学学院病毒学国家重点实验室教授博导\n2025-至今重庆医科大学附属儿童医院国家临床医学研究中心教授博导\n荣誉与获奖\n国家海外高层次青年人才,广东省科技进步奖一等奖,重庆市高层次人才\n国内外学术团体任职\n武汉生物物理学会理事长\n中国生物物理学会人工智能生物学分会委员\n基金项目\n1.新型病原体模式识别受体、信号分子及调控分子的发现、作用机制与结构研究。国家重大科学研究计划（973）课题，课题负责人，结题\n2.T细胞受体识别肿瘤多肽疫苗的结构和功能研究。国家自然科学基金，负责人，结题\n3.高效多肽疫苗激活T细胞抗肿瘤的复合物结构研究及分子机制。国家自然科学基金，负责人，结题\n4.银屑病自身免疫原的T细胞受体识别。国家自然科学基金，负责人，结题\n5.Cas12aPAM识别严格性和脱靶的结构功能关系研究。国家自然科学基金，负责人，在研\n6.宿主抗结核免疫相关关键生物大分子的调控机制。国家重点研发计划，骨干,在研\n7.小型高保真Cas12a的结构基础和改造设计。国家自然科学基金,负责人，在研\n代表性论文(*通讯作者，#共同第一作者)\n1.Chen P, Wu Y, Wang H, Liu H, Zhou J, Lei J, Sun Z, Yin L*. Highly parallel profiling of the activities and specificities of Cas12a variants in human cells. Nat Commun. 2025 Mar 28;16(1):3022\n2.Chen Q, Pang M, Chen P, Zhou Z, Lei J, He B, Sun Z, Paek C, Jing B, Wu Y, Liu S, Chen Y, Yin L*. High-fidelity CRISPR/Cas12a dual-crRNA screening reveals novel synergistic interactions in hepatocellular carcinoma. Clin Transl Med. 2024 Jul;14(7):e1758\n3.Wang H, Zhou J, Lei J, Mo G, Wu Y, Liu H, Pang Z, Du M, Zhou Z, Paek C, Sun Z, Chen Y, Wang Y*, Chen P*, Yin L*. Engineering of a compact, high-fidelity EbCas12a variant that can be packaged with its crRNA into an all-in-one AAV vector delivery system. PLoS Biol. 2024 May 30;22(5):e3002619.\n4.Fang XX, Wei P, Zhao K, Sheng ZC, Song BL*, Yin L*, Luo J*. Fatty acid-binding proteins 3, 7, and 8 bind cholesterol and facilitate its egress from lysosomes. J Cell Biol. 2024 Apr 1;223(4):e202211062.\n5.Chen P, Zhou J, Liu H, Zhou E, He B, Wu Y, Wang H, Sun Z, Paek C, Lei J, Chen Y*, Zhang X*, Yin L*. Engineering of Cas12a nuclease variants with enhanced genome-editing specificity. PLoS Biol. 2024 Mar 14;22(3):e3002514.\n6.Wang Y, Sun Z, Ping J, Tang J, He B, Chang T, Zhou Q, Yuan S, Tang Z, Li X, Lu Y, He R, He X, Liu Z*, Yin L*, Wu N*. Cell volume controlled by LRRC8A-formed volume-regulated anion channels fine-tunes T cell activation and function. Nat Commun. 2023 Nov 4;14(1):7075.\n7.Zhao W, Lei J, Ke S, Chen Y, Xiao J, Tang Z, Wang L, Ren Y, Alnaggar M, Qiu H, Shi W, Yin L*, Chen Y*. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215). EClinicalMedicine. 2023 Nov 14;66:102315.\n8.Zhou J, Chen P, Wang H, Liu H, Li Y, Zhang Y, Wu Y, Paek C, Sun Z, Lei J, Yin L*. Cas12a variants designed for lower genome-wide off-target effect through stringent PAM recognition. Molecular Therapy. 2022，30（1）\n9.Wei P, Jordan K, Buhrman J, Lei J, Deng H, Marrack P, Dai S, Kappler JW*, Slansky J*, Yin L*. Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cell in cancer. PNAS. 2021 Jun 8;118(23):e2100588118.\n10.Bai P, Zhou Q, Wei P, Bai H, Chan SK, Kappler JW, Marrack P, Yin L*. Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation. Sci China Life Sci. 2021 Dec;64(12):2144-2152\n11.Qu Z, Zhou J, Zhou Y, Xie Y, Jiang Y, Wu J, Luo Z, Liu G, Yin L*, Zhang XL*. Mycobacterial EST12 activates a RACK1-NLRP3-gasdermin D pyroptosis immune pathway. Science Advances. 2020 Oct 23;6(43):eaba4733.\n12.Chen P, Zhou J, Wan Y, Liu H, Li Y, Liu Z, Wang H, Lei J, Zhao K, Zhang Y, Wang Y, Zhang X, Yin L*. A Cas12a ortholog with stringent PAM recognition followed by low off-target editing rates for genome editing. Genome Biology. 2020 Mar 25;21(1):78\n13.Wei P, Yang Y, Liu Z, Luo Z, Tu W, Han J, Deng Y, Yin L*. Characterization of Autoantigen Presentation by HLA-C*06:02 in Psoriasis. J Invest Dermatol. 2017 Oct; 137(10):2238-2241\n14. Zhou Z#, Lei J#*, Fang J#, Chen P, Zhou J, Wang H, Sun Z, Chen Y*, Yin L*. Dihydroartemisinin remodels tumor micro-environment and improves cancer immunotherapy through inhibiting cyclin-dependent kinases. Int Immunopharmacol. 2024 Sep 30;139:112637.\n15. Sun Z, He B, Yang Z, Huang Y, Duan Z, Yu C, Dan Z, Paek C, Chen P, Zhou J, Lei J, Wang F*, Liu B*, Yin L*. Cost-Effective Whole Transcriptome Sequencing Landscape and Diagnostic Potential Biomarkers in Active Tuberculosis. ACS Infect Dis. 2024 Jun 14;10(6):2318-2332.\n16. Fang J, Lei J, He B, Wu Y, Chen P, Sun Z, Wu N, Huang Y, Wei P, Yin L*, Chen Y*. Decoding the transcriptional heterogeneity, differentiation lineage, clinical significance in tissue-resident memory CD8 T cell of the small intestine by single-cell analysis. J Transl Med. 2024 Feb 25;22(1):203.\n17. Lei J, Zhou Z, Fang J, Sun Z, He M, He B, Chen Q, Paek C, Chen P, Zhou J, Wang H, Tang M, Yin L*, Chen Y*. Aspirin induces immunogenic cell death and enhances cancer immunotherapy in colorectal cancer. Int Immunopharmacol. 2023 Aug;121:110350\n18. Lei J, Yang Y, Lu Z, Pan H, Fang J, Jing B, Chen Y*, Yin L*. Taming metabolic competition via glycolysis inhibition for safe and potent tumor immunotherapy. Biochem Pharmacol. 2022 Aug;202:115153.\n19. Liu Y, Lei J, San D, Yang Y, Paek C, Xia Z, Chen Y*, Yin L*. Structural basis for unusual TCR CDR3βusage against an immunodominant HIV-1 Gag protein peptide restricted to an HLA-B*81:01 molecule. Front. Immunol. 2022 Jan 31;13:822210\n20. Yang Y，Bai H, Wu Y, Chen P, Zhou J, Lei J, Ye X, Brown A, Zhou X, Shu T, Chen Y, Wei P*,Yin L*. The Activating receptor KIR2DS2 bound to HLA-C1 reveals the novel recognition features of activati"